Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest oncology group phase II study, SWOG 9019

Journal of Clinical Oncology

Volumn 20, Issue 16, 2002, Pages 3454-3460

  Albain, Kathy S ^a   Crowley, John J ^a   Turrisi III, Andrew T ^a   Gandara, David R ^a   Farrar, William B ^a   Clark, Joseph I ^a   Beasley, Kristie R ^a   Livingston, Robert B ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURGICAL APPROACH; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 0037102282     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.03.055     Document Type: Article

References (25)

1. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer
2. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis of a randomized trial in 353 patients
3. Improved survival in stage III non-small cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial
4. RTOG 88-08/ECOG 4588: Preliminary results of a phase III trial in regionally advanced unresectable non-small cell lung cancer
5. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: A randomized study
6. Is clinical stage III non-small cell lung cancer a homogeneous group?
7. Lack of apparent difference in outcome between clinically staged IIIA and IIIB non-small cell lung cancer treated with radiotherapy
8. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-small cell lung cancer: Mature results of Southwest Oncology Group Phase II Study 8805
9. Nonparametric estimation from incomplete observations
10. Combined chemotherapy radiotherapy treatment in unresectable non-small cell lung cancer: Radiation Therapy Oncology Group (RTOG) experience
11. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III nonsmall-cell lung cancer
12. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) 9410
13. Long-term survival after concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery in bulky, stages IIIA (N2) and IIIB non-small cell lung cancer: 6-year outcomes from Southwest Oncology Group Study 8805
14. Interim update of the National Cancer Institute High Priority North American Intergroup Trial 0139 (RTOG 93-09) for stage IIIA (N2) non-small cell lung cancer: A phase III comparison of concurrent chemotherapy plus standard radiotherapy versus concurrent chemotherapy plus radiotherapy followed by surgical resection
15. Randomized trial of surgery versus radiotherapy in patients with stage IIIA non-small cell lung cancer after a response to induction chemotherapy: Intergroup study 08941
16. Induction therapy for locally advanced non-small cell lung cancer
17. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: Mature results of a phase II trial
18. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center Study 94-001
19. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced nonsmall cell lung cancer: A phase I study
20. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
21. CALGB Study 9431: A randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer
22. Sequential phase II studies of paclitaxel +/- carboplatin and radiation therapy (+/- hyperfractionation) for locally advanced non-small cell lung cancer
23. Combined modality therapy for unresectable stage III non-small cell lung cancer: New chemotherapy combinations
24. Prolonged survival in pathologic stage IIIB non-small cell lung cancer with concurrent chemoradiotherapy followed by consolidation docetaxel: A phase II study (S9504) of the Southwest Oncology Group
25. Induction and concurrent carboplatin/paclitaxel with dose escalated thoracic conformal radiotherapy in stage IIIA/B non-small cell lung cancer: A phase I/II trial